Brainstorm Cell Therapeutics Inc.
BCLI· OTC
BCLIBrainstorm Cell Therapeutics Inc.
Filed May 15, 2026 · 10-Q · 45 days after period end · 0001104659-26-062648
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$2.13M | -$2.86M | -$3.40M | -$5.06M |
| EPS Diluted | -$0.19 | -$0.45 | -$0.75 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Brainstorm Cell Therapeutics Inc. · CIK 1137883 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end
